Dr. Junlin Yi 易俊林
Chief Physician, Associate Professor
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Intensity-modulated radiation therapy and comprehensive treatment for nasopharyngeal carcinoma and head and neck tumors.
Dr. Yi is a Chief Physician and Associate Professor at the Cancer Hospital, Chinese Academy of Medical Sciences. Dr. Yi earned a medical degree from Hunan Medical University in 1993 and a PhD from Peking Union Medical College in 2001. Following work as a visiting scholar at Kyoto University Hospital, Dr. Yi specialized in radiotherapy for head and neck malignancies, contributing to national treatment guidelines and clinical research.
Name order: in Chinese the family name comes first (Yi Junlin). Papers usually list the name as Junlin Yi or Yi J.
Selected publications
137 papers on PubMed matched by name and affiliation; 44 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Radiat Oncol Biol Phys, 2026 (senior author): Childhood Nasopharyngeal Carcinoma: A Rare Disease With Distinct Features and Favorable Prognosis. PubMed 41990887
- Front Immunol, 2026 (senior author): Treatment-related lymphopenia predicts long-term survival in locally advanced head and neck cancer: Post-Hoc analysis of a randomized phase III trial. PubMed 42741172
- Otolaryngol Head Neck Surg, 2026 (first author): Evaluation of Prognostic Factors in Adult Sinonasal Rhabdomyosarcoma With Consideration of Resection Status. PubMed 42212552
- Ther Adv Med Oncol, 2026 (senior author): Reply to: Comment on "Combination of immunotherapy-based systemic therapy and radiotherapy achieves durable response and favorable survival in recurrent head and neck cancer". PubMed 42539925
- Cancer Immunol Immunother, 2026 (senior author): Neoadjuvant immunochemotherapy followed by definitive radiotherapy in locally advanced head and neck squamous cell carcinoma: two-year survival outcomes. PubMed 42283875
- Head Neck, 2025 (senior author): Patterns of Regional Failure in Patients With Oral Cavity Squamous Cell Carcinoma After Radical Surgery: Insight for Neck Management Optimization. PubMed 40539334
- Ther Adv Med Oncol, 2025 (senior author): Combination of immunotherapy-based systemic therapy and radiotherapy achieves durable response and favorable survival in recurrent head and neck cancer. PubMed 40948911
- NPJ Digit Med, 2025 (senior author): Treatment response-adapted risk index model for survival prediction and adjuvant chemotherapy selection in nonmetastatic nasopharyngeal carcinoma. PubMed 40890288
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion